Fluorodopa (18F)

Fluorodopa (¹⁸F), also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).^[2]

Not to be confused with Florbetapir (18F).

Fluorodopa (¹⁸F)

Clinical data
Trade names	Fluorodopa F18
Other names	6-fluoro-L-DOPA, FDOPA
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Fluorodopa
Routes of administration	Intravenous
ATC code	V09IX05 (WHO)
Legal status
Legal status	US: ℞-only[1]
Identifiers
IUPAC name (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid
CAS Number	92812-82-3
PubChem CID	56494
DrugBank	DB13848
ChemSpider	50970
UNII	2C598205QX
KEGG	D04220
ChEBI	CHEBI:49166
ChEMBL	ChEMBL3400972
CompTox Dashboard (EPA)	DTXSID90226257
Chemical and physical data
Formula	C9H10FNO4
Molar mass	215.180 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N
InChI InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1 Key:PAXWQORCRCBOCU-RPDRGXCHSA-N

The most common side effects are injection site pain.^[1]

Medical uses

Fluorodopa (¹⁸F) is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes.^[1]

History

In October 2019, Fluorodopa (¹⁸F) was approved in the United States for the visual detection of certain nerve cells in adults with suspected Parkinsonian syndromes.^[3][4]

The US Food and Drug Administration approved Fluorodopa F 18 based on evidence from one clinical trial of 56 participants with suspected Parkinsonian syndromes.^[3] The trial was conducted at one clinical site in the United States.^[3]